New oral vaccine aims to boost immune attack on aggressive breast cancer
Disease control
Recruiting now
This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and help…
Phase: PHASE1, PHASE2 • Sponsor: NEC Bio B.V • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC